Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

被引:194
作者
Breeman, WAP [1 ]
de Jong, M
Kwekkeboom, DJ
Valkema, R
Bakker, WH
Kooij, PPM
Visser, TJ
Krenning, EP
机构
[1] Erasmus Sch Ctr Rotterdam, Dept Nucl Med, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus Sch Ctr Rotterdam, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands
关键词
somatostatin receptor subtypes; imaging; therapy; DTPA; DOTA;
D O I
10.1007/s002590100502
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualisation of neuroendocrine tumours and their metastases. A new application is the use of radiolabelled analogues for somatostatin receptor-mediated therapy. This paper presents a review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumours. New somatostatin analogues, new chelators, "new" radionuclides and combinations thereof are also discussed. Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy.
引用
收藏
页码:1421 / 1429
页数:9
相关论文
共 63 条
[1]   Treatment of neuroendocrine GEP tumours with somatostatin analogues - A review [J].
Arnold, R ;
Simon, B ;
Wied, M .
DIGESTION, 2000, 62 :84-91
[2]   The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules [J].
Blum, JE ;
Handmaker, H ;
Rinne, NA .
CHEST, 1999, 115 (01) :224-232
[3]  
Breeman WAP, 1999, INT J CANCER, V83, P657, DOI 10.1002/(SICI)1097-0215(19991126)83:5<657::AID-IJC15>3.0.CO
[4]  
2-Y
[5]  
Breeman WAP, 1996, J NUCL MED, V37, P108
[6]  
BREEMAN WAP, 1995, J NUCL MED, V36, P623
[7]  
Buchsbaum DJ, 1999, CLIN CANCER RES, V5, p3048S
[8]   Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide:: implications for internal radiotherapy with 90Y-DOTATOC [J].
Cremonesi, M ;
Ferrari, M ;
Zoboli, S ;
Chinol, M ;
Stabin, MG ;
Orsi, F ;
Maecke, HR ;
Jermann, E ;
Robertson, C ;
Fiorenza, M ;
Tosi, G ;
Paganelli, G .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (08) :877-886
[9]  
de Jong M, 1998, CANCER RES, V58, P437
[10]   Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide:: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide [J].
Decristoforo, C ;
Cholewinski, W ;
Donnemiller, E ;
Riccabona, G ;
Moncayo, R ;
Mather, SJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (10) :1580-1580